Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000231988 | SCV000287639 | likely benign | Colorectal cancer, susceptibility to, 10 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000231988 | SCV000489130 | uncertain significance | Colorectal cancer, susceptibility to, 10 | 2016-08-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000479381 | SCV000571819 | uncertain significance | not provided | 2023-04-19 | criteria provided, single submitter | clinical testing | Segregates with disease in affected individuals in the literature, but also identified in several control subjects without history of colorectal cancer or polyps (Rosner et al., 2018); Some missense variants in POLD1 have been recognized as an underlying cause of Polymerase Proofreading-Associated Polyposis (PPAP); however, there are no data at this time to support that loss-of-function variants confer the same cancer risks; This variant is associated with the following publications: (PMID: 25986922, 33809179, 30086056, 23263490) |
Ambry Genetics | RCV000576035 | SCV000671025 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-06 | criteria provided, single submitter | clinical testing | The p.R195* variant (also known as c.583C>T), located in coding exon 4 of the POLD1 gene, results from a C to T substitution at nucleotide position 583. This changes the amino acid from an arginine to a stop codon within coding exon 4. In one study, this alteration was detected in 1/132 Jewish patients with colorectal adenomas and/or early-onset, mismatch repair proficient colorectal cancer as well as in 5/5685 control subjects without colorectal adenomas or cancer (Rosner G et al. Dis. Colon Rectum, 2018 09;61:1073-1079). This alteration is expected to result in protein truncation or nonsense-mediated mRNA decay. However, loss of function of POLD1 has not been established as a mechanism of disease. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV000479381 | SCV001502262 | uncertain significance | not provided | 2022-09-01 | criteria provided, single submitter | clinical testing | POLD1: PP3 |
Institute for Clinical Genetics, |
RCV000479381 | SCV002010548 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000576035 | SCV002534691 | likely benign | Hereditary cancer-predisposing syndrome | 2021-01-18 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV002465586 | SCV002761046 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005016638 | SCV005650284 | uncertain significance | Colorectal cancer, susceptibility to, 10; Mandibular hypoplasia-deafness-progeroid syndrome; Immunodeficiency 120 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004737363 | SCV005346491 | uncertain significance | POLD1-related disorder | 2024-05-12 | no assertion criteria provided | clinical testing | The POLD1 c.583C>T variant is predicted to result in premature protein termination (p.Arg195*). This variant has been reported in the heterozygous state in an individual with early-onset MMR-proficient colorectal cancer (Table 4 in Rosner et al. 2018. PubMed ID: 30086056). However, the established mechanism for POLD1-related malignancy involves missense mutations that disrupt the protein proof-reading domain (Palles et al. 2013. PubMed ID: 23263490) and there is currently no evidence to suggest that truncating variants cause disease. In the gnomAD public population database this variant has been reported in up to 0.16 % of alleles in a subpopulation and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/239357/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |